Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Ajlan Atasoy"'
Autor:
Vahit Özmen, Ajlan Atasoy, Erhan Gökmen, Mustafa Özdoğan, Nilufer Güler, Cihan Uras, Engin Ok, Orhan Demircan, Abdurrahman Işıkkdoğan, Neslihan Cabioğlu, Fatma Şen, Pınar Saip
Publikováno v:
European Journal of Breast Health, Vol 12, Iss 3, Pp 107-111 (2016)
Objective: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aime
Externí odkaz:
https://doaj.org/article/63dcdacd07c740df98431314a5d9e8d7
Autor:
Konstantin Laktionov, Chong-Jen Yu, Kye Young Lee, Frances A. Shepherd, Roy S. Herbst, Filippo de Marinis, Yi-Long Wu, Zhijie Wang, Jonathan W. Goldman, Charuwan Akewanlop, Christian Grohé, Terufumi Kato, Thomas John, Huu Vinh Vu, Margarita Majem, Laura Bonanno, Ajlan Atasoy, Masahiro Tsuboi, Lingmin Zeng, Sang-We Kim, Shun Lu, Manuel Domine
Publikováno v:
Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0661f5dd358265eaada556e742780a9
https://doi.org/10.1016/j.jtho.2021.10.014
https://doi.org/10.1016/j.jtho.2021.10.014
Autor:
Konstantin Laktionov, Yi-Long Wu, Shun Lu, Kye-Young Lee, Thomas John, Terufumi Kato, Masahiro Tsuboi, Chong-Jen Yu, Jonathan W. Goldman, Manuel Domine, Yuri Rukazenkov, C. Grohe, Lingmin Zeng, Laura Bonanno, Jie He, Huu-Vinh Vu, Sang-We Kim, Frances A. Shepherd, Filippo de Marinis, Margarita Majem, Ajlan Atasoy, Rachel Hodge, Roy S. Herbst, Charuwan Akewanlop
Publikováno v:
New England Journal of Medicine. 383:1711-1723
BACKGROUND: Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a37d4ddf3885cfacbcfd109270c823
https://doi.org/10.1056/nejmoa2027071
https://doi.org/10.1056/nejmoa2027071
Autor:
Laura Bonanno, Jonathan W. Goldman, Chong-Jen Yu, Sang-We Kim, Christian Grohé, Ajlan Atasoy, Filippo de Marinis, Thomas John, Yuri Rukazenkov, Shun Lu, Terufumi Kato, Manuel Domine, Kye Young Lee, Margarita Majem, Huu-Vinh Vu, Charuwan Akewanlop, Rachel Hodge, Frances A. Shepherd, Roy S. Herbst, Masahiro Tsuboi, Lingmin Zeng, Yi-Long Wu, Konstantin Laktionov
Publikováno v:
Future Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2fc84416d56be2d35e49b5abf6cc022
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5211
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5211
Autor:
Jean-Marie Ledeine, Massimo Aglietta, Dana Backlund Cardin, Eric Van Cutsem, Ka Yeung Mark Wong, M. Luisa Limon, Alain Hendlisz, Andrea Spallanzani, Pilar García-Alfonso, Bart Neyns, Michael J. Overman, Tomislav Dragovich, Ajlan Atasoy, Usman Shah, Sara Lonardi, Vittorina Zagonel, Heinz-Josef Lenz
11 Background: In the phase 2 CheckMate 142 trial, nivolumab plus low-dose ipilimumab provided robust and durable clinical benefit and was well tolerated as first-line therapy for microsatellite instability-high/DNA mismatch repair deficient (MSI-H/d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad8b09f3c4ea50db1b3393c15794c9bd
https://biblio.vub.ac.be/vubir/nivolumab-plus-lowdose-ipilimumab-as-firstline-therapy-in-microsatellite-instabilityhighdna-mismatch-repair-deficient-metastatic-colorectal-cancer-clinical-update(09026f0b-b882-462a-a1ac-4589b80e28aa).html
https://biblio.vub.ac.be/vubir/nivolumab-plus-lowdose-ipilimumab-as-firstline-therapy-in-microsatellite-instabilityhighdna-mismatch-repair-deficient-metastatic-colorectal-cancer-clinical-update(09026f0b-b882-462a-a1ac-4589b80e28aa).html
Autor:
Annett Maderer, Murielle Mauer, Carmela Caballero, Eric Van Cutsem, Thomas Thomaidis, István Láng, Markus Moehler, Arno Schad, João Freire, Jestinah. M. Mahachie John, Arnaud Roth, Ajlan Atasoy, Manfred P. Lutz
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:733-739
HER2-targeted therapy with trastuzumab and (CF/X) prolonged overall survival (OS) in metastatic HER2neu+ gastric carcinoma (GC). Lapatinib inhibits both EGFR and HER2neu. We investigated the efficacy and safety of lapatinib with epirubicin (E) + CF/X
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7998b6d7537bf295f03fabe914de2cd6
https://doi.org/10.1007/s00280-018-3667-8
https://doi.org/10.1007/s00280-018-3667-8
Autor:
Nischala Ammannagari, Ajlan Atasoy
Publikováno v:
Journal of Gastrointestinal Oncology. 9:196-207
Gastroesophageal (GE) cancers continue to be a significant cause of mortality globally. Despite therapeutic advances in oncology, the prognosis of advanced GE cancer remains exceedingly poor. Immunotherapy has caused a major paradigm shift in the fie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81c96622de9e888dd333d52f740ffadb
https://doi.org/10.21037/jgo.2017.06.12
https://doi.org/10.21037/jgo.2017.06.12
Autor:
Jean-Marie Ledeine, Michael J. Overman, M. Luisa Limon, Pilar García-Alfonso, Eric Van Cutsem, Alain Hendlisz, Heinz-Josef Lenz, Massimo Aglietta, Tomislav Dragovich, Bart Neyns, Usman Shah, Ka Yeung Mark Wong, Dana Backlund Cardin, Andrea Spallanzani, Sara Lonardi, Vittorina Zagonel, Ajlan Atasoy
3521 Background: In the phase 2 CheckMate 142 trial, NIVO + low-dose IPI provided robust and durable clinical benefit and was well tolerated as 1L therapy for MSI-H/dMMR mCRC (Lenz et al. Ann Oncol 2018;29:LBA18). Longer follow-up data will be presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f35e9a1c4b461e86513bfb759c916441
https://doi.org/10.1200/jco.2019.37.15_suppl.3521
https://doi.org/10.1200/jco.2019.37.15_suppl.3521
Autor:
Michael J. Overman, Ka Yeung Mark Wong, Eric Van Cutsem, Thierry André, Heinz-Josef Lenz, Magali Svrcek, Massimo Aglietta, Ming Lei, Michael B. Sawyer, Bart Neyns, Andrew G. Hill, Michael A. Morse, Ajlan Atasoy, Sara Lonardi, Raymond S. McDermott, Alain Hendlisz, Fabio Gelsomino, Scott Kopetz, Huanyu Zhao
635 Background: In the phase II CheckMate-142 trial, NIVO + low-dose IPI (1 mg/kg) provided meaningful clinical benefit in previously treated MSI-H/dMMR mCRC pts after a median follow-up of 13.4 mo. Here, we present long-term follow-up (median 25.4 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4708a03f02f4cba062417e74c6809521
https://doi.org/10.1200/jco.2019.37.4_suppl.635
https://doi.org/10.1200/jco.2019.37.4_suppl.635
Autor:
S.-B. Kim, F. De Marinis, Roy S. Herbst, Manuel Domine, Jie He, Jonathan W. Goldman, Frances A. Shepherd, Ajlan Atasoy, C. Grohe, C. Yan, Huu-Vinh Vu, Konstantin Laktionov, Masahiro Tsuboi, Toshikazu Kato, Y-L. Wu, Margarita Majem, C. Yu, Charuwan Akewanlop, Thomas John
Publikováno v:
Annals of Oncology. 31:S1177
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a532616685c39fb14a5927083c7b4089
https://doi.org/10.1016/j.annonc.2020.08.2279
https://doi.org/10.1016/j.annonc.2020.08.2279